search
Back to results

Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women (ROMA:Women)

Primary Purpose

Heart Diseases, Coronary Artery Disease, Coronary Artery Bypass Grafting

Status
Recruiting
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Single arterial graft
Multiple arterial grafting
Sponsored by
Weill Medical College of Cornell University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Heart Diseases

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  1. Women patients ≥18 years old.
  2. Isolated coronary artery bypass grafting.
  3. Primary (first time) cardiac surgery procedure.
  4. Significant disease of the left main coronary artery or of the left anterior descending and the circumflex coronary system with or without disease of the right coronary artery.

Exclusion Criteria:

  • Male gender
  • Single graft
  • Emergency operation
  • Myocardial infarction within 72 hours of surgery
  • Left ventricular ejection fraction < 35%
  • Any concomitant cardiac or non-cardiac procedure
  • Previous cardiac surgery
  • Preoperative severe end-organ dysfunction (dialysis, liver failure, respiratory failure), cancer or any co-morbidity that reduces life expectancy to less than 5 years.
  • Inability to use the saphenous vein or to use both radial and right internal thoracic arteries
  • Anticipated need for coronary thrombo-endarterectomy
  • Planned hybrid revascularization

Sites / Locations

  • University of ColoradoRecruiting
  • Baystate HealthRecruiting
  • Nebraska Heart Hospital
  • University of Nebraska Medical CenterRecruiting
  • Weill Cornell MedicineRecruiting
  • Icahn School of Medicine, Mount Sinai
  • Lenox Hill Hospital
  • Cleveland Clinic Foundation
  • Ohio State UniversityRecruiting
  • Allegheny General Hospital
  • Medical University of GrazRecruiting
  • Innsbruck Medical UniversityRecruiting
  • Medical University of ViennaRecruiting
  • Krankenhaus Nord Vienna North HospitalRecruiting
  • Institute of Cardiology Porto Alegre
  • Heart Institute University of São Paulo
  • Instituto Dante Pazzanese de Cardiologia
  • St. Boniface General HospitalRecruiting
  • Horizon Health Network - Saint John Regional HospitalRecruiting
  • Hamilton General HospitalRecruiting
  • London Health SciencesRecruiting
  • University of Ottawa Heart InstituteRecruiting
  • Health Sciences North
  • Sunnybrook Health SciencesRecruiting
  • Toronto General Hospital
  • Montreal Heart InstituteRecruiting
  • University Hospital of MontrealRecruiting
  • Royal Victoria HospitalRecruiting
  • Institut Universitaire de Cardiologie et de Pneumologie de QuébecRecruiting
  • Fuwai Hospital China
  • Jilin Heart Hospital ChinaRecruiting
  • Ruijin Hospital Shanghai Jiao Tong University School of MedicineRecruiting
  • Teda Hospital Tianjin China
  • University Hospital DubravaRecruiting
  • University Hradec Králové
  • General University Hospital, Prague
  • Universitäts-Herzzentrum Bad Krozingen Freiburg
  • HDZ NRW Bad Oeynhausen Germany
  • Essen University
  • Duisburg Heart Center
  • Dusseldorf UniversityRecruiting
  • University Hospital Erlangen
  • Frankfurt University
  • University Hospital of Giessen and MarburgRecruiting
  • University Medical Center of Göttingen
  • Jena University HospitalRecruiting
  • Heart Center Herzzentrum, LeipzigRecruiting
  • Robert-Bosch-Hospital Stuttgart Germany
  • Krankenhaus der Barmherzigen Brüder TrierRecruiting
  • G Kuppuswamy Naidu Memorial Hospital (GKNM)Recruiting
  • Star Hospitals - Hyderabad, IndiaRecruiting
  • Rambam Health Care CampusRecruiting
  • Anthea HospitalRecruiting
  • Fondazione Poliambulanza
  • Maria Cecilia Hospital GVM
  • European HospitalRecruiting
  • Universita' Cattolica del Sacro CuoreRecruiting
  • Ospedale Le Molinette, Torino
  • Tokyo Medical and Dental University
  • Saitama Medical University Japan
  • Severance Cardiovascular Hospital, Yonsei University College of Medicine
  • Maastricht University Medical CentreRecruiting
  • Medical University of SilesiaRecruiting
  • Zbigniew Religa Lower Silesian Heart Disease CentreRecruiting
  • University Hospital CoimbraRecruiting
  • Centro Hospitalar Lisboa Ocidental
  • Centro Hospitalar e Universitário Sao João
  • Dedinje Cardiovascular InstituteRecruiting
  • National University of Singapore
  • Hospital Universitario del VinalopoRecruiting
  • Hospital Clinic de BarcelonaRecruiting
  • National Taiwan University Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Single Arterial Graft (SAG) group

Multiple Arterial Graft (MAG) group

Arm Description

Patients in this group will receive a single arterial graft which will be the left internal thoracic artery. Additional grafts used in this group will all be venous grafts.

Patients in the group will receive multiple arterial grafts. All patients will receive at least two arterial grafts, the left internal thoracic artery with the addition of either the right internal thoracic artery or the radial artery as the second conduit. Some patients may receive additional arterial grafts consisting of the radial artery, the right internal thoracic artery, or the right gastroepiploic artery.

Outcomes

Primary Outcome Measures

Primary outcome for aim 1: Death from any cause, any stroke, non-procedural myocardial infarction, repeat revascularization and hospital readmission for acute coronary syndrome or heart failure.
The primary outcome for aim 1 will be a composite of the first occurrence of death from any cause, any stroke, non-procedural myocardial infarction (>48 hours after surgery), repeat revascularization and hospital readmission for acute coronary syndrome or heart failure.
Primary outcome for aim 2: Disease-specific quality of life
Assessed using the Seattle Angina Questionnaire (SAQ), a validated 19-item questionnaire that measures five domains related to coronary disease: angina frequency, physical limitations, quality of life, angina stability, and treatment satisfaction. Scores range from 0 to 100 with higher scores indicating fewer symptoms and better health status. The minimum clinically important difference on the SAQ is 5 points. The primary endpoint for aim 2 is the absolute change in the Seattle Angina Questionnaire (SAQ) at 12 months compared to baseline.

Secondary Outcome Measures

Death from any cause, any stroke, non-procedural myocardial infarction, and repeat revascularization.
One of the secondary outcomes for aim 1: It will be a composite of the first occurrence of death from any cause, any stroke, non-procedural myocardial infarction (>48 hours after surgery), and repeat revascularization. This is the primary outcome of the parent ROMA trial.
Death from cardiac cause, any stroke, non-procedural myocardial infarction, repeat revascularization and hospital readmission for acute coronary syndrome or heart failure.
Another secondary outcome for aim 1: It will be a composite of the first occurrence of death from cardiac cause, any stroke, non-procedural myocardial infarction (>48 hours after surgery), repeat revascularization, and hospital readmission for acute coronary syndrome or heart failure.
Death from any cause
Another secondary outcome for aim 1: Death will be considered to be cardiac unless a definite non-cardiac cause is identified.
Stroke
Another secondary outcome for aim 1: Based on the American Heart Association/American Stroke Association Expert Consensus stroke definition, stroke will be identified in case of: pathological, imaging, or other objective evidence of cerebral ischemic injury in a defined vascular distribution; OR clinical evidence of cerebral ischemic injury based on symptoms persisting ≥24 hours or until death, and other etiologies excluded.
Non-procedural myocardial infarction
Another secondary outcome for aim 1: Based on the 4th Universal Definition, non-periprocedural myocardial infarction will be identified in case of detection of rise and/or fall of cardiac biomarkers with at least one value above the 99th percentile of the upper reference limit together with evidence of myocardial ischemia with at least one of the following: symptoms of ischemia electrocardiogram changes indicative of new ischemia (new ST-T changes or new left bundle branch block) development of pathological Q waves in the electrocardiogram imaging evidence of new loss of viable myocardium or new regional wall motion abnormality.
Repeat revascularization
Another secondary outcome for aim 1: Repeat revascularization will include any percutaneous or surgical revascularization on a grafted coronary artery after the initial operation.
Readmission for acute coronary syndrome
Another secondary outcome for aim 1: Prolonged ischemic symptoms at rest (usually ≥10 minutes in duration), or accelerating pattern of chest pain that occurs with a lower activity threshold (CCS class III or IV) considered to be myocardial ischemia upon final diagnosis resulting in an unscheduled visit to a healthcare facility resulting in an overnight stay generally within 24 hours of the most recent symptoms, cardiac biomarkers not meeting MI criteria, and ECG or angiographic evidence of ischemia.
Readmission for heart failure
Another secondary outcome for aim 1: While patients may have multiple simultaneous disease processes, for the outcome event of heart failure requiring hospitalization, the diagnosis of congestive heart failure would need to be the primary process. Heart failure (HF) requiring hospitalization is defined as an event that meets the following criteria: i. Requires hospitalization AND ii. Clinical symptoms of heart failure AND iii. Physical signs of heart failure AND iv. Need for additional/increased therapy AND v. No other non-cardiac etiology (such as chronic obstructive pulmonary disease, hepatic cirrhosis, acute renal failure, or venous insufficiency) and no other cardiac etiology (such as pulmonary embolus, cor pulmonale, primary pulmonary hypertension, or congenital heart disease) for signs or symptoms are identified.
Generic quality of life according to the Short Form Health Survey (SF-12v2)
Secondary outcomes for aim 2: The SF-12v12 measures eight dimensions of health: physical functioning, role limitations due to physical problems, bodily pain, vitality, general health perception, social function, role limitations due to emotional problems, and mental health. Scores for each domain range from 0 to 100 with higher scores indicating better health status. The SF-12v2 has two summary measures: physical and mental self-perceived health with norm-based methods that standardize the score to a mean of 50 and standard deviation of 10.
Generic quality of life according to EuroQuol-5D (EQ-5D)
Secondary outcomes for aim 2: EQ-5D is a five-item instrument to assess health status in the following five dimensions: mobility, self-care, usual activity, pain or discomfort, and anxiety or depression. Individual domain scores will be converted to a summary index representing utility weights, which allow conduct of cost-effectiveness analyses.
Mental and physical health symptoms according to PROMIS instruments
Secondary outcomes for aim 2: Physical and mental health symptoms and physical functioning will be measured with standardized PROMIS instruments, including: Pain interference, Neuropathic Pain, Fatigue, Sleep disturbance, Depression, Anxiety, and Physical Function. A mean of 50 and a standard deviation of 10 represent the general population in the US.

Full Information

First Posted
October 10, 2019
Last Updated
July 5, 2023
Sponsor
Weill Medical College of Cornell University
Collaborators
New York Presbyterian Hospital, Sunnybrook Health Sciences Centre, Cedars-Sinai Medical Center, Columbia University, Duke University
search

1. Study Identification

Unique Protocol Identification Number
NCT04124120
Brief Title
Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women
Acronym
ROMA:Women
Official Title
Randomized Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women (ROMA:Women) Trial
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Recruiting
Study Start Date
April 17, 2023 (Actual)
Primary Completion Date
March 2030 (Anticipated)
Study Completion Date
March 2030 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Weill Medical College of Cornell University
Collaborators
New York Presbyterian Hospital, Sunnybrook Health Sciences Centre, Cedars-Sinai Medical Center, Columbia University, Duke University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The central hypothesis of ROMA:Women is that the use of multiple arterial grafting (MAG) will improve clinical outcomes and quality of life (QOL) compared to single arterial grfating (SAG). The specific aims of ROMA:Women are: Aim 1: Determine the impact of MAG vs SAG on major adverse cardiac and cerebrovascular events in women undergoing coronary artery bypass grfating (CABG). The investigators will compare major adverse cardiac and cerebrovascular events (death, stroke, non-procedural myocardial infarction, repeat revascularization, and hospital readmission for acute coronary syndrome or heart failure) in a cohort of 2,000 women randomized 1:1 to MAG or SAG (690 from the parent ROMA trial + 1,310 from ROMA:Women). Differences by important clinical and surgical subgroups (patients younger or older than 70 years, diabetics, racial and ethnic minorities, on vs off pump CABG, type of arterial grafts used) will also be evaluated. The women enrolled in the ongoing ROMA trial (anticipated to be approximately 690) will be included in ROMA:Women, increasing efficiency and reducing enrollment time. Hypothesis 1.0. MAG will reduce the incidence of major adverse cardiac and cerebrovascular events. Hypothesis 1.1. The improvement with MAG will be consistent across key subgroups. Aim 2: Determine the impact of MAG vs SAG on generic and disease-specific QOL, physical and mental health symptoms in women undergoing CABG. The investigators will compare generic (SF-12, EQ-5D) and disease-specific (Seattle Angina Questionnaire) QOL and physical and mental health symptoms (PROMIS-29) in a sub-cohort of 500 women randomized 1:1 to MAG or SAG (including those enrolled in ROMA:QOL). Differences by important subgroups (as defined above) will also be evaluated. Hypothesis 2.0. MAG will improve generic and disease-specific QOL compared to SAG. Hypothesis 2.1. MAG will improve physical and mental health symptoms compared to SAG. Hypothesis 2.2. The improvement with MAG will be consistent across key subgroups.
Detailed Description
ROMA:Women will leverage the infrastructure and the existing women population of the ROMA trial. ROMA:Women has two key Aims. In Aim 1, the investigators will compare major adverse cardiac and cerebrovascular events (death, stroke, non-procedural myocardial infarction, repeat revascularization and hospital readmission for acute coronary syndrome or heart failure) in a cohort of 2,000 women randomized 1:1 to MAG or SAG (690 from the parent ROMA trial + 1,310 from ROMA:Women). In Aim 2, the investigators will compare generic (SF-12, EQ-5D) and disease-specific (Seattle Angina Questionnaire) QOL and physical and mental health symptoms (PROMIS-29) in a sub-cohort of 500 women randomized 1:1 to MAG or SAG. Differences by important subgroups (patients younger or older than 70 years, diabetics, racial and ethnic minorities, on vs off pump CABG, type of arterial grafts used) will also be evaluated. ROMA:Women is a two-arm, international, multi-center, randomized clinical trial nested in the ROMA trial. ROMA:Women will include all the women enrolled in the parent ROMA trial and will leverage the existing ROMA infrastructure including clinical trial unit, database, case report forms (CRF), randomization system, site training resources, informed consent forms (ICF), regulatory approvals, Central Events Review Committee (CEC) processes/personnel, network of participating sites, site PIs, and study coordinators. The planned randomization procedure, interventions and treatment arms, outcome assessments and follow-up protocol of ROMA:Women are identical to those of the currently ongoing parent ROMA trial. The sites participating in ROMA will continue enrollment of women after the completion of the ROMA trial and additional sites will also be opened to reach the target sample size of ROMA:Women.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Heart Diseases, Coronary Artery Disease, Coronary Artery Bypass Grafting

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Patients undergoing coronary artery bypass surgery will be in one of two groups. One group will receive a single arterial graft and the second group will receive two or more arterial grafts.
Masking
Outcomes Assessor
Masking Description
The endpoint assessors will be blinded to treatment allocation (PROBE).
Allocation
Randomized
Enrollment
2000 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Single Arterial Graft (SAG) group
Arm Type
Experimental
Arm Description
Patients in this group will receive a single arterial graft which will be the left internal thoracic artery. Additional grafts used in this group will all be venous grafts.
Arm Title
Multiple Arterial Graft (MAG) group
Arm Type
Experimental
Arm Description
Patients in the group will receive multiple arterial grafts. All patients will receive at least two arterial grafts, the left internal thoracic artery with the addition of either the right internal thoracic artery or the radial artery as the second conduit. Some patients may receive additional arterial grafts consisting of the radial artery, the right internal thoracic artery, or the right gastroepiploic artery.
Intervention Type
Procedure
Intervention Name(s)
Single arterial graft
Intervention Description
This interventions consists of patients receiving the left internal thoracic artery to the left anterior descending coronary artery of the heart. In addition to the left internal thoracic artery patients will receive venous grafts for all additional grafting.
Intervention Type
Procedure
Intervention Name(s)
Multiple arterial grafting
Intervention Description
This intervention consists of the patient receiving the left internal thoracic artery to the left anterior descending coronary artery of the heart. The second arterial graft (right internal thoracic artery or radial artery) will be directed to the major branch of the circumflex. Additional grafts will include saphenous veins or arterial conduits.
Primary Outcome Measure Information:
Title
Primary outcome for aim 1: Death from any cause, any stroke, non-procedural myocardial infarction, repeat revascularization and hospital readmission for acute coronary syndrome or heart failure.
Description
The primary outcome for aim 1 will be a composite of the first occurrence of death from any cause, any stroke, non-procedural myocardial infarction (>48 hours after surgery), repeat revascularization and hospital readmission for acute coronary syndrome or heart failure.
Time Frame
Postoperatively, minimum 2.5 year follow-up
Title
Primary outcome for aim 2: Disease-specific quality of life
Description
Assessed using the Seattle Angina Questionnaire (SAQ), a validated 19-item questionnaire that measures five domains related to coronary disease: angina frequency, physical limitations, quality of life, angina stability, and treatment satisfaction. Scores range from 0 to 100 with higher scores indicating fewer symptoms and better health status. The minimum clinically important difference on the SAQ is 5 points. The primary endpoint for aim 2 is the absolute change in the Seattle Angina Questionnaire (SAQ) at 12 months compared to baseline.
Time Frame
Postoperatively, minimum 2.5 year follow-up
Secondary Outcome Measure Information:
Title
Death from any cause, any stroke, non-procedural myocardial infarction, and repeat revascularization.
Description
One of the secondary outcomes for aim 1: It will be a composite of the first occurrence of death from any cause, any stroke, non-procedural myocardial infarction (>48 hours after surgery), and repeat revascularization. This is the primary outcome of the parent ROMA trial.
Time Frame
Postoperatively, minimum 2.5 year follow-up
Title
Death from cardiac cause, any stroke, non-procedural myocardial infarction, repeat revascularization and hospital readmission for acute coronary syndrome or heart failure.
Description
Another secondary outcome for aim 1: It will be a composite of the first occurrence of death from cardiac cause, any stroke, non-procedural myocardial infarction (>48 hours after surgery), repeat revascularization, and hospital readmission for acute coronary syndrome or heart failure.
Time Frame
Postoperatively, minimum 2.5 year follow-up
Title
Death from any cause
Description
Another secondary outcome for aim 1: Death will be considered to be cardiac unless a definite non-cardiac cause is identified.
Time Frame
Postoperatively, minimum 2.5 year follow-up
Title
Stroke
Description
Another secondary outcome for aim 1: Based on the American Heart Association/American Stroke Association Expert Consensus stroke definition, stroke will be identified in case of: pathological, imaging, or other objective evidence of cerebral ischemic injury in a defined vascular distribution; OR clinical evidence of cerebral ischemic injury based on symptoms persisting ≥24 hours or until death, and other etiologies excluded.
Time Frame
Postoperatively, minimum 2.5 year follow-up
Title
Non-procedural myocardial infarction
Description
Another secondary outcome for aim 1: Based on the 4th Universal Definition, non-periprocedural myocardial infarction will be identified in case of detection of rise and/or fall of cardiac biomarkers with at least one value above the 99th percentile of the upper reference limit together with evidence of myocardial ischemia with at least one of the following: symptoms of ischemia electrocardiogram changes indicative of new ischemia (new ST-T changes or new left bundle branch block) development of pathological Q waves in the electrocardiogram imaging evidence of new loss of viable myocardium or new regional wall motion abnormality.
Time Frame
> 48 hours postoperatively, minimum 2.5 year follow-up
Title
Repeat revascularization
Description
Another secondary outcome for aim 1: Repeat revascularization will include any percutaneous or surgical revascularization on a grafted coronary artery after the initial operation.
Time Frame
Postoperatively, minimum 2.5 year follow-up
Title
Readmission for acute coronary syndrome
Description
Another secondary outcome for aim 1: Prolonged ischemic symptoms at rest (usually ≥10 minutes in duration), or accelerating pattern of chest pain that occurs with a lower activity threshold (CCS class III or IV) considered to be myocardial ischemia upon final diagnosis resulting in an unscheduled visit to a healthcare facility resulting in an overnight stay generally within 24 hours of the most recent symptoms, cardiac biomarkers not meeting MI criteria, and ECG or angiographic evidence of ischemia.
Time Frame
Postoperatively, minimum 2.5 year follow-up
Title
Readmission for heart failure
Description
Another secondary outcome for aim 1: While patients may have multiple simultaneous disease processes, for the outcome event of heart failure requiring hospitalization, the diagnosis of congestive heart failure would need to be the primary process. Heart failure (HF) requiring hospitalization is defined as an event that meets the following criteria: i. Requires hospitalization AND ii. Clinical symptoms of heart failure AND iii. Physical signs of heart failure AND iv. Need for additional/increased therapy AND v. No other non-cardiac etiology (such as chronic obstructive pulmonary disease, hepatic cirrhosis, acute renal failure, or venous insufficiency) and no other cardiac etiology (such as pulmonary embolus, cor pulmonale, primary pulmonary hypertension, or congenital heart disease) for signs or symptoms are identified.
Time Frame
Postoperatively, minimum 2.5 year follow-up
Title
Generic quality of life according to the Short Form Health Survey (SF-12v2)
Description
Secondary outcomes for aim 2: The SF-12v12 measures eight dimensions of health: physical functioning, role limitations due to physical problems, bodily pain, vitality, general health perception, social function, role limitations due to emotional problems, and mental health. Scores for each domain range from 0 to 100 with higher scores indicating better health status. The SF-12v2 has two summary measures: physical and mental self-perceived health with norm-based methods that standardize the score to a mean of 50 and standard deviation of 10.
Time Frame
Postoperatively, minimum 2.5 year follow-up
Title
Generic quality of life according to EuroQuol-5D (EQ-5D)
Description
Secondary outcomes for aim 2: EQ-5D is a five-item instrument to assess health status in the following five dimensions: mobility, self-care, usual activity, pain or discomfort, and anxiety or depression. Individual domain scores will be converted to a summary index representing utility weights, which allow conduct of cost-effectiveness analyses.
Time Frame
Postoperatively, minimum 2.5 year follow-up
Title
Mental and physical health symptoms according to PROMIS instruments
Description
Secondary outcomes for aim 2: Physical and mental health symptoms and physical functioning will be measured with standardized PROMIS instruments, including: Pain interference, Neuropathic Pain, Fatigue, Sleep disturbance, Depression, Anxiety, and Physical Function. A mean of 50 and a standard deviation of 10 represent the general population in the US.
Time Frame
Postoperatively, minimum 2.5 year follow-up
Other Pre-specified Outcome Measures:
Title
Other recorded outcomes (safety endpoints)
Description
30-day mortality and major postoperative complications (revision for bleeding, perioperative MI (<48 hours after surgery), need for dialysis, need for tracheostomy, and surgical site complications).
Time Frame
Within 30 days of surgery or during index hospitalization, whichever is longer.

10. Eligibility

Sex
Female
Gender Based
Yes
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Women patients ≥18 years old. Isolated coronary artery bypass grafting. Primary (first time) cardiac surgery procedure. Significant disease of the left main coronary artery or of the left anterior descending and the circumflex coronary system with or without disease of the right coronary artery. Exclusion Criteria: Male gender Single graft Emergency operation Myocardial infarction within 72 hours of surgery Left ventricular ejection fraction < 35% Any concomitant cardiac or non-cardiac procedure Previous cardiac surgery Preoperative severe end-organ dysfunction (dialysis, liver failure, respiratory failure), cancer or any co-morbidity that reduces life expectancy to less than 5 years. Inability to use the saphenous vein or to use both radial and right internal thoracic arteries Anticipated need for coronary thrombo-endarterectomy Planned hybrid revascularization
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Mario Gaudino, Prof/PhD/MD
Phone
212.746.1812
Email
mfg9004@med.cornell.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Stephen Fremes, Prof/MD
Phone
1 416 480 6073
Email
stephen.fremes@sunnybrook.ca
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mario Gaudino, Prof/PhD/MD
Organizational Affiliation
Weill Medical College of Cornell University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Stephen Fremes, MD
Organizational Affiliation
Sunnybrook Health Sciences Centre
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Ruth Masterson Creber, RN, PhD
Organizational Affiliation
Columbia University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
C. Noel Bairey Merz, MD
Organizational Affiliation
Cedars-Sinai
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Karla Ballman, PhD
Organizational Affiliation
Weill Medical College of Cornell University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Sean O'Brien, PhD
Organizational Affiliation
Duke University
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Colorado
City
Aurora
State/Province
Colorado
ZIP/Postal Code
80045
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jessica Rove, MD
Facility Name
Baystate Health
City
Springfield
State/Province
Massachusetts
ZIP/Postal Code
01199
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Daniel Engelman, MD
Facility Name
Nebraska Heart Hospital
City
Lincoln
State/Province
Nebraska
ZIP/Postal Code
68526
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Omar Nass
Facility Name
University of Nebraska Medical Center
City
Omaha
State/Province
Nebraska
ZIP/Postal Code
68198
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Aleem Siddique, MD
Facility Name
Weill Cornell Medicine
City
New York
State/Province
New York
ZIP/Postal Code
10021
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mario Gaudino, Prof/PhD/MD
Phone
212-746-1812
Email
mfg9004@med.cornell.edu
Facility Name
Icahn School of Medicine, Mount Sinai
City
New York
State/Province
New York
ZIP/Postal Code
10029
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
John Puskas, MD
Facility Name
Lenox Hill Hospital
City
New York
State/Province
New York
ZIP/Postal Code
10075
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nirav Patel, MD
Facility Name
Cleveland Clinic Foundation
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44195
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Faisal Bakaeen, MD
Facility Name
Ohio State University
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43210
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jovan Bozinovski, MD
Facility Name
Allegheny General Hospital
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15212
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Scott Halbreiner, MD
Facility Name
Medical University of Graz
City
Graz
ZIP/Postal Code
8010
Country
Austria
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Daniel Zimpfer, MD
Facility Name
Innsbruck Medical University
City
Innsbruck
ZIP/Postal Code
6020
Country
Austria
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Elfriede Ruttmann-Ulmer, MD
Facility Name
Medical University of Vienna
City
Vienna
ZIP/Postal Code
1090
Country
Austria
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sigrid Sandner, MD
Facility Name
Krankenhaus Nord Vienna North Hospital
City
Vienna
ZIP/Postal Code
1210
Country
Austria
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Berhard Winkler, MD
Facility Name
Institute of Cardiology Porto Alegre
City
Porto Alegre
ZIP/Postal Code
9062000
Country
Brazil
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Renato Kalil, MD
Facility Name
Heart Institute University of São Paulo
City
São Paulo
ZIP/Postal Code
05508
Country
Brazil
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Fabio B Jatene, MD
Facility Name
Instituto Dante Pazzanese de Cardiologia
City
Vila Mariana
ZIP/Postal Code
04012-909
Country
Brazil
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Renato T Arnoni, MD
Facility Name
St. Boniface General Hospital
City
Winnipeg
State/Province
Manitoba
ZIP/Postal Code
R2H 2A6
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rakesh Arora, MD
Facility Name
Horizon Health Network - Saint John Regional Hospital
City
Saint John
State/Province
New Brunswick
ZIP/Postal Code
E2L 4L2
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Craig Brown, MD
Facility Name
Hamilton General Hospital
City
Hamilton
State/Province
Ontario
ZIP/Postal Code
L8L 2X2
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Andre Lamy, MD
Facility Name
London Health Sciences
City
London
State/Province
Ontario
ZIP/Postal Code
N6A 5A5
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
David Nagpal, MD
Facility Name
University of Ottawa Heart Institute
City
Ottawa
State/Province
Ontario
ZIP/Postal Code
K1Y 4W7
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marc Ruel, MD
Facility Name
Health Sciences North
City
Sudbury
State/Province
Ontario
ZIP/Postal Code
P3E 5J1
Country
Canada
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bindu Bittira, MD
Facility Name
Sunnybrook Health Sciences
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M4N 3M5
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Stephen E Fremes, MD
Facility Name
Toronto General Hospital
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5G 2C4
Country
Canada
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Vivek Rao, MD
Facility Name
Montreal Heart Institute
City
Montréal
State/Province
Quebec
ZIP/Postal Code
H1T 1C8
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Philippe Demers, MD
Facility Name
University Hospital of Montreal
City
Montréal
State/Province
Quebec
ZIP/Postal Code
H2X 3E4
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nicolas Noiseux, MD
Facility Name
Royal Victoria Hospital
City
Montréal
State/Province
Quebec
ZIP/Postal Code
H4A 3J1
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kevin Lachapelle, MD
Facility Name
Institut Universitaire de Cardiologie et de Pneumologie de Québec
City
Ste Foy
State/Province
Quebec
ZIP/Postal Code
G1V 4G5
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Pierre Voisine, MD
Facility Name
Fuwai Hospital China
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100037
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Zhe Zheng, MD
Facility Name
Jilin Heart Hospital China
City
Changchun
State/Province
Jilin
ZIP/Postal Code
130052
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Massimo Lemma, MD
Facility Name
Ruijin Hospital Shanghai Jiao Tong University School of Medicine
City
Shanghai
State/Province
Shanghai
ZIP/Postal Code
200025
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Qiang Zhao, MD
Facility Name
Teda Hospital Tianjin China
City
Tianjin
State/Province
Tianjin
ZIP/Postal Code
300456
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Guo-Wei He, MD
Facility Name
University Hospital Dubrava
City
Zagreb
ZIP/Postal Code
10000
Country
Croatia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Igor Rudez, MD
Facility Name
University Hradec Králové
City
Hradec Králové
ZIP/Postal Code
500 03
Country
Czechia
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jan Vojacek, MD
Facility Name
General University Hospital, Prague
City
Nové Město
ZIP/Postal Code
128 08
Country
Czechia
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tomas Prskavec, MD
Facility Name
Universitäts-Herzzentrum Bad Krozingen Freiburg
City
Bad Krozingen
State/Province
Baden-Wuerttemberg
ZIP/Postal Code
79189
Country
Germany
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Martin Czerny, MD
Facility Name
HDZ NRW Bad Oeynhausen Germany
City
Bad Oeynhausen
ZIP/Postal Code
32545
Country
Germany
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marcus-Andre Deutsch, MD
Facility Name
Essen University
City
Duisburg
ZIP/Postal Code
47057
Country
Germany
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mathias Thielmann, MD
Facility Name
Duisburg Heart Center
City
Duisburg
ZIP/Postal Code
47137
Country
Germany
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jochen Börgermann, MD
Facility Name
Dusseldorf University
City
Düsseldorf
ZIP/Postal Code
40225
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alexander Assmann, MD
Facility Name
University Hospital Erlangen
City
Erlangen
ZIP/Postal Code
91054
Country
Germany
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ehab Nooh, MD
Facility Name
Frankfurt University
City
Frankfurt
ZIP/Postal Code
60323
Country
Germany
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Thomas Holubec, MD
Facility Name
University Hospital of Giessen and Marburg
City
Gießen
ZIP/Postal Code
35385
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Andreas Boening, MD
Facility Name
University Medical Center of Göttingen
City
Göttingen
ZIP/Postal Code
37075
Country
Germany
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bernd Danner, MD
Facility Name
Jena University Hospital
City
Jena
ZIP/Postal Code
07743
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Torsten Doenst, MD
Facility Name
Heart Center Herzzentrum, Leipzig
City
Leipzig
ZIP/Postal Code
04289
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michael Borger, MD
Facility Name
Robert-Bosch-Hospital Stuttgart Germany
City
Stuttgart
ZIP/Postal Code
70376
Country
Germany
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marc Albert, MD
Facility Name
Krankenhaus der Barmherzigen Brüder Trier
City
Trier
ZIP/Postal Code
54292
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
John D Terrence, MD
Facility Name
G Kuppuswamy Naidu Memorial Hospital (GKNM)
City
Coimbatore
State/Province
Tamil Nadu
ZIP/Postal Code
641037
Country
India
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Chandra Padmanabhan, MD
Facility Name
Star Hospitals - Hyderabad, India
City
Hyderabad
State/Province
Telangana
ZIP/Postal Code
500034
Country
India
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Gopichand Mannam, MD
Facility Name
Rambam Health Care Campus
City
Haifa
ZIP/Postal Code
3109601
Country
Israel
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Gil Bolotin, MD
Facility Name
Anthea Hospital
City
Bari
ZIP/Postal Code
70124
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Giuseppe Speziale, MD
Facility Name
Fondazione Poliambulanza
City
Brescia
ZIP/Postal Code
25124
Country
Italy
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Gianni Troise, MD
Facility Name
Maria Cecilia Hospital GVM
City
Cotignola
ZIP/Postal Code
48033
Country
Italy
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alberto Albertini, MD
Facility Name
European Hospital
City
Roma
ZIP/Postal Code
00149
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ruggero De Paulis, MD
Facility Name
Universita' Cattolica del Sacro Cuore
City
Roma
ZIP/Postal Code
00168
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Massimo Massetti, MD
Facility Name
Ospedale Le Molinette, Torino
City
Torino
ZIP/Postal Code
10126
Country
Italy
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mauro Rinaldi, MD
Facility Name
Tokyo Medical and Dental University
City
Bunkyō-Ku
State/Province
Tokyo
ZIP/Postal Code
113-8510
Country
Japan
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hirokuni Arai, MD
Facility Name
Saitama Medical University Japan
City
Saitama
ZIP/Postal Code
350-0451
Country
Japan
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hiroyuki Nakajima, MD
Facility Name
Severance Cardiovascular Hospital, Yonsei University College of Medicine
City
Seúl
ZIP/Postal Code
03722
Country
Korea, Republic of
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kyung-Jong Yoo, MD
Facility Name
Maastricht University Medical Centre
City
Maastricht
ZIP/Postal Code
6229
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Roberto Lorusso, MD
Facility Name
Medical University of Silesia
City
Katowice
ZIP/Postal Code
40-055
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marek Deja, MD
Facility Name
Zbigniew Religa Lower Silesian Heart Disease Centre
City
Zabrze
ZIP/Postal Code
41-800
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Romuald Cichon, MD
Facility Name
University Hospital Coimbra
City
Coimbra
ZIP/Postal Code
3004-561
Country
Portugal
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Manuel Antunes, MD
Facility Name
Centro Hospitalar Lisboa Ocidental
City
Lisboa
ZIP/Postal Code
1300-598
Country
Portugal
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Miguel Sousa Uva, MD
Facility Name
Centro Hospitalar e Universitário Sao João
City
Porto
ZIP/Postal Code
4200-319
Country
Portugal
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Adelino Leite-Moreira, MD
Facility Name
Dedinje Cardiovascular Institute
City
Belgrade
ZIP/Postal Code
11000
Country
Serbia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Milan Milojevic, MD
Facility Name
National University of Singapore
City
Singapore
ZIP/Postal Code
119077
Country
Singapore
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Theodoros Kofidis, MD
Facility Name
Hospital Universitario del Vinalopo
City
Elx
State/Province
Alicante
ZIP/Postal Code
03293
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jose Albors Martin, MD
Facility Name
Hospital Clinic de Barcelona
City
Barcelona
ZIP/Postal Code
08036
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jorge Alcocer, MD
Facility Name
National Taiwan University Hospital
City
Zhongzheng
State/Province
Taipei
ZIP/Postal Code
100229
Country
Taiwan
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yih-Sharng Chen, MD

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Primary outcome data under request
IPD Sharing Time Frame
From publication until the third year after publication
IPD Sharing Access Criteria
Research scope
Citations:
PubMed Identifier
3484393
Citation
Loop FD, Lytle BW, Cosgrove DM, Stewart RW, Goormastic M, Williams GW, Golding LA, Gill CC, Taylor PC, Sheldon WC, et al. Influence of the internal-mammary-artery graft on 10-year survival and other cardiac events. N Engl J Med. 1986 Jan 2;314(1):1-6. doi: 10.1056/NEJM198601023140101.
Results Reference
background
PubMed Identifier
14726042
Citation
Tatoulis J, Buxton BF, Fuller JA. Patencies of 2127 arterial to coronary conduits over 15 years. Ann Thorac Surg. 2004 Jan;77(1):93-101. doi: 10.1016/s0003-4975(03)01331-6.
Results Reference
background
PubMed Identifier
10220677
Citation
Lytle BW, Blackstone EH, Loop FD, Houghtaling PL, Arnold JH, Akhrass R, McCarthy PM, Cosgrove DM. Two internal thoracic artery grafts are better than one. J Thorac Cardiovasc Surg. 1999 May;117(5):855-72. doi: 10.1016/S0022-5223(99)70365-X.
Results Reference
background
PubMed Identifier
11567701
Citation
Taggart DP, D'Amico R, Altman DG. Effect of arterial revascularisation on survival: a systematic review of studies comparing bilateral and single internal mammary arteries. Lancet. 2001 Sep 15;358(9285):870-5. doi: 10.1016/S0140-6736(01)06069-X.
Results Reference
background
PubMed Identifier
24916209
Citation
Yi G, Shine B, Rehman SM, Altman DG, Taggart DP. Effect of bilateral internal mammary artery grafts on long-term survival: a meta-analysis approach. Circulation. 2014 Aug 12;130(7):539-45. doi: 10.1161/CIRCULATIONAHA.113.004255. Epub 2014 Jun 10.
Results Reference
background
PubMed Identifier
22070836
Citation
Hillis LD, Smith PK, Anderson JL, Bittl JA, Bridges CR, Byrne JG, Cigarroa JE, Disesa VJ, Hiratzka LF, Hutter AM Jr, Jessen ME, Keeley EC, Lahey SJ, Lange RA, London MJ, Mack MJ, Patel MR, Puskas JD, Sabik JF, Selnes O, Shahian DM, Trost JC, Winniford MD; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines; American Association for Thoracic Surgery; Society of Cardiovascular Anesthesiologists; Society of Thoracic Surgeons. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, Society of Cardiovascular Anesthesiologists, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2011 Dec 6;58(24):e123-210. doi: 10.1016/j.jacc.2011.08.009. Epub 2011 Nov 7. No abstract available.
Results Reference
background
PubMed Identifier
25173339
Citation
Authors/Task Force members; Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Juni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014 Oct 1;35(37):2541-619. doi: 10.1093/eurheartj/ehu278. Epub 2014 Aug 29. No abstract available.
Results Reference
background
PubMed Identifier
26680310
Citation
Aldea GS, Bakaeen FG, Pal J, Fremes S, Head SJ, Sabik J, Rosengart T, Kappetein AP, Thourani VH, Firestone S, Mitchell JD; Society of Thoracic Surgeons. The Society of Thoracic Surgeons Clinical Practice Guidelines on Arterial Conduits for Coronary Artery Bypass Grafting. Ann Thorac Surg. 2016 Feb;101(2):801-9. doi: 10.1016/j.athoracsur.2015.09.100. Epub 2015 Dec 8.
Results Reference
background
PubMed Identifier
24686003
Citation
Benedetto U, Raja SG, Albanese A, Amrani M, Biondi-Zoccai G, Frati G. Searching for the second best graft for coronary artery bypass surgery: a network meta-analysis of randomized controlled trialsdagger. Eur J Cardiothorac Surg. 2015 Jan;47(1):59-65; discussion 65. doi: 10.1093/ejcts/ezu111. Epub 2014 Mar 30.
Results Reference
background

Learn more about this trial

Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women

We'll reach out to this number within 24 hrs